BACKGROUND
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces risk of heart and kidney outcomes in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Heart failure is the leading cause of hospitalization in patients with CKD. Here we evaluated whether the reduction in estimated g...
T. Shafi, S. Anker, B. Pitt et al.· European Journal of Heart Fa...· 0 citations
BACKGROUND
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...
R. Inciardi, J. Ostrominski, B. Claggett et al.· Journal of Cardiac Failure· 0 citations
A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.
Nelson Wang, B. Claggett, M. Pfeffer et al.· Nature Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.